ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted?
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.
Jan 13, 2016
The 20 Something’s Stock Portfolio
Let’s have some fun. There’s nothing dull about this portfolio.
Jul 28, 2015
You Didn't Miss This Best Ideas Newsletter Email Alert, Did You?
Let's take a look at this email alert from July 24, 2013. What would be the returns two years hence?
Sep 3, 2014
Performance Update: The Valuentum Buying Index
Let’s take a look at how the Valuentum Buying Index has performed.
Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings.
Apr 23, 2014
Throwing In the Towel on Intuitive Surgical
Management no longer has the visibility it once had.
Apr 1, 2014
Intuitive Surgical Soars!
Let’s take a look at the news that sent Best Ideas portfolio holding Intuitive Surgical higher today.
Mar 18, 2014
Focus on Process over Outcome
We wanted to share an excellent piece on the importance of focusing on process over outcome in investing.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.